Health
Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction – News-Medical.Net
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That’s the finding of the EMPEROR-Reduced trial presented in a Hot Line session today at ESC Congress 2020.
The EMPEROR-Reduced trial was designed to evaluate the effects of empagliflozin 10 mg once daily (as compared with placebo) in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were already rece…
-
General23 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
General9 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
General21 hours agoRobin Williams’s daughter begs fans to stop making AI content of her father
-
Noosa News23 hours agoBrisbane man lured to death over ‘forbidden’ marriage, jury told